Welcome to the e-CCO Library!

P416: Metabolite measurement for thiopurine therapy in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Sánchez Rodríguez*, R. Ríos León, Á. Flores de Miguel, A. Guerrero García, A. Albillos Martínez, A. López Sanromán

Created: Thursday, 21 February 2019, 9:14 AM
P416: Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Plevris N., Manship T.A., Deekae A., Jones G.R., Noble C.L., Satsangi J., Shand A.G., Arnott I.D., Lees C.W.

Created: Wednesday, 20 February 2019, 10:36 AM
P416: The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United Kingdom.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Patel, K.V.(1)*;Salmon, P.(2);Marin-Jiménez, I.(3);Thessen, M.(4);Kligys, K.(4);Sharma, D.(4);Sanchez Gonzalez, Y.(4);Kershaw, J.(5);
Created: Friday, 14 July 2023, 11:05 AM
P416: Use of DXA in children with Inflammatory Bowel Disease – a large single centre study
Year: 2021
Source: ECCO'21 Virtual
Authors: Jois, A.(1);Perera, S.(2);Simm, P.(3);Alex, G.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P417 Do ACE inhibitors and angiotensin II receptor blockers improve disease outcomes in inflammatory bowel disease?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. FAIRBRASS1, D. Hoshen1, A.C. Ford1,2, D. Gracie1

Created: Thursday, 30 January 2020, 10:12 AM
P417: 10 years of endoscopic therapy of symptomatic Crohn’s disease stenoses: a retrospective analysis of long-term results
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Aichinger1, K. Rothfuss1, M. Koch1, E. F. Stange1, J. G. Albert1, C. Schäfer1

Created: Friday, 22 February 2019, 9:41 AM
P417: Crohn disease recurrences: Nothing new under the sun?
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Giulii Capponi*, E. Rausa, M. Lotti, F. Bianco, G. Panyor, A. Indriolo, P. Ravelli, L. Campanati

Created: Thursday, 21 February 2019, 9:14 AM
P417: Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wetwittayakhlang, P.(1)*;Karkout, K.(2);Tselekouni, P.(1);Aljabri, R.(1);Bessissow, T.(1);Afif, W.(1);Wild, G.(1);Bitton, A.(1);LakatosPhD, P.L.(3,4);
Created: Friday, 14 July 2023, 11:05 AM
P417: Long-term deep remission after adalimumab discontinuation in Crohn’s disease patients.
Year: 2021
Source: ECCO'21 Virtual
Authors: Melotti, L.(1);Rizzello, F.(1);Calabrese, C.(1);Dussias, N.(1);Gionchetti, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P417: Non-invasive assessment of liver fibrosis by transient elastography and AST to ALT ratio in patients with Crohn's disease treated with methotrexate
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Peixoto A., Silva M., Morais R., Liberal R., Gonçalves R., Lopes S., Macedo G.

Created: Wednesday, 20 February 2019, 10:36 AM
P417: Seroconversion after COVID-19 Vaccination in Inflammatory Bowel Disease Patients
Year: 2022
Source: ECCO'22
Authors: Horvath , M.(1);Csontos , Á.A.(1);Sárközi , M.(1);Cseprekal , O.(1);Szijártó , A.(1);Miheller , P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P417: Ulcerative colitis: let’s talk about extent
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Vaz*, M. Eusébio, A. Antunes, P. Queirós, T. Gago, T. Belo, P. Caldeira, H. Guerreiro

Created: Friday, 22 February 2019, 9:49 AM
P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Reinisch1, J. Brodbeck2, R. Galien3, E. Grant2, X. Hébuterne4, M. Kłopocka5, R. Petryka6, X. Roblin7, A. Serone2, C. Tasset8, O.K. Yoon2, S. Zaboli2, S. Vermeire9

Created: Thursday, 30 January 2020, 10:12 AM
P418: Development and validation of a digital health platform (IBD NutriCare) for telenutrition in patients with Inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Gupta, A.(1);Singh, N.(1);Madan, D.(1);Farooqui, M.(1);Singh, N.(1);Singh, M.(1);Virmani, S.(1);Verma, M.(1);Bajaj, A.(1);Markandey, M.(1);kante, B.(1);Vuyyuru, S.K.(1);Kumar, P.(1);Sahu, P.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
Created: Friday, 11 February 2022, 3:52 PM
P418: Does capsule endoscopy impact clinical management in established Crohn’s Disease?
Year: 2021
Source: ECCO'21 Virtual
Authors: Elosua Gonzalez, A.(1);Rullan Iriarte, M.(1);Rubio Iturria, S.(2);Oquiñena Legaz, S.(2);Rodríguez Gutiérrez, C.(2);Macías Mendizábal, E.(2);Borda Martín, A.(2);Fernández-Urién Sainz, I.(2);Nantes Castillejo, Ó.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P418: Dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with Mayo endoscopic subscore of one improves long-term prognosis: a one-year multicentre, open-label, randomized controlled trial.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Aoki, Y.(1)*;Fukuda, T.(1,2,3);Kiyohara, H.(1,2);Yokoyama, A.(4);Nakazawa, A.(4);Yoshimatsu, Y.(1);Sugimoto, S.(1);Nanki, K.(1);Mikami, Y.(1);Fukuhara, K.(5);Mizuno, S.(1);Sujino, T.(6);Mutaguchi, M.(6);Takabayashi, K.(6);Morohoshi, Y.(3);Hosoda, Y.(7);Ogata, H.(6);Iwao, Y.(5);Naganuma, M.(1,8);Kanai, T.(1);
Created: Friday, 14 July 2023, 11:05 AM
P418: Pharmacodynamic biomarkers demonstrate dose-dependent pharmacological activity of the IL-22Fc fusion protein UTR1147A in healthy volunteers in a phase 1a clinical trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lekkerkerker A., Harder B., Kulkarni P., Zhao R., Choi M., Noyes A., Polihrom A., Fillos D., Rae J., Danilenko D., Stefanich E., Herman A., Lu T.

Created: Wednesday, 20 February 2019, 10:36 AM
P418: Predictive factors of surgery in the course of Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Agar*, M. Medhioub, S. Jardak, L. Hamzaoui, A. Khsiba, M.M. Azzouz

Created: Thursday, 21 February 2019, 9:14 AM
P418: Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Higgins*1, D. Ginsburg2, K. Gilder3, K. Gilder3, B. Walsh3, B. English3, S. Turner3, P. Klassen3, S. Hanauer4, C. Barish5, B. Yacyshyn6

Created: Friday, 22 February 2019, 9:41 AM
P418: Ulcerative colitis and end-stage liver disease in children with primary sclerosing cholangitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Czubkowski*, M. Wozniak, J. Pawlowska, I. Jankowska, J. Kierkus

Created: Friday, 22 February 2019, 9:49 AM